Materials & Resources » Chemicals | Hubei Biocause Pharmaceutical Co. Ltd.

Hubei Biocause Pharmaceutical Co. Ltd. A | Mutual Funds

Mutual Funds that own Hubei Biocause Pharmaceutical Co. Ltd. A

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Emerging Markets Stock Index Fund
3,883,200
0.28%
0
0%
07/31/2018
Huatai - PineBridge CSI 300 ETF Units
2,486,900
0.18%
162,700
0.1%
12/31/2017
China AMC CSI 300 Index ETF (CN)
2,318,700
0.17%
269,600
0.1%
12/31/2017
Harvest SZSE SME-CHINEXT 300 ETF
2,306,200
0.17%
154,600
0.1%
12/31/2017
1,613,870
0.12%
1,550,870
1.33%
12/31/2017
ChinaAMC ETF Series - CSI 300 Index ETF
1,381,664
0.1%
174,900
0.11%
12/31/2017
1,340,800
0.1%
1,340,800
0.2%
12/31/2017
1,197,400
0.09%
-230,300
0.74%
12/31/2017
Deutsche X-trackers Harvest CSI 300 China A-Shares ETF
741,700
0.06%
0
0.09%
09/05/2018
KraneShares Bosera MSCI China A Share ETF
724,090
0.05%
0
0.21%
09/06/2018

About Hubei Biocause Pharmaceutical Co.

View Profile
Address
No. 132 Yangwan Road
Jingmen Hubei 448000
China
Employees -
Website http://www.biocause.com
Updated 07/08/2019
Hubei Biocause Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of chemical products and medicinal raw materials. Its products include homatropine hydrobromide, thiotriazoline, lercanidipine hydrochloride, barnidipine hydrochloride, mitoxantrone hydrochloride, hyoscyamine sulfate, balsalazide sodium, oxaprozin, homatropine methyl bromide, flumazenil, milrinone, granisetron hydrochloride and others. The company was founded on November 18, 1993 and is headquartered in Jingmen, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.